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Abstract
Background: The evidence for a "diabesity" epidemic is accumulating worldwide but population-
based data are still scarce in the African region. We assessed the prevalence, awareness and control
of diabetes (DM) in the Seychelles, a rapidly developing country in the African region. We also
examined the relationship between body mass index, fasting serum insulin and DM.
Methods: Examination survey in a sample representative of the entire population aged 25–64 of
the Seychelles, attended by 1255 persons (participation rate of 80.2%). An oral glucose tolerance
test (OGTT) was performed in individuals with fasting blood glucose between 5.6 and 6.9 mmol/l.
Diabetes mellitus (DM), impaired fasting glucose (IFG) and impaired glucose tolerance (IGT) were
defined along criteria of the ADA. Prevalence estimates were standardized for age.
Results: The prevalence of DM was 11.5% and 54% of persons with DM were aware of having DM.
Less than a quarter of all diabetic persons under treatment were well controlled for glycemia
(HbA1c), blood pressure or LDL-cholesterol. The prevalence of IGT and IFG were respectively
10.4% and 24.2%. The prevalence of excess weight (BMI ≥ 25 kg/m2) and obesity (BMI ≥ 30 kg/m2)
was respectively 60.1% and 25.0%. Half of all DM cases in the population could be attributed to
excess weight.
Conclusion: We found a high prevalence of DM and pre-diabetes in a rapidly developing country
in the African region. The strong association between overweight and DM emphasizes the
importance of weight control measures to reduce the incidence of DM in the population. High rates
of diabetic persons not aware of having DM in the population and insufficient cardiometabolic
control among persons treated for DM stress the need for intensifying health care for diabetes.
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It is estimated that diabetes mellitus (DM) accounts cur-
rently for 5.2% of all deaths worldwide [1]. The number
of people with DM is expected to double from 175 mil-
lion in 2000 to 353 million in 2030 [2]. The largest
increase is expected to occur in developing countries, with
305 million individuals likely to have DM by 2030 [2].
The prevalence of DM in adults varies markedly between
different populations, e.g. 2.6% in Nigeria [3], 18% in
Mauritius [4], and more than 50% in Pima Indians in the
U.S. [5]. These differences have been related to unfavora-
ble trends in factors such as overweight and sedentary
habits, as demonstrated in longitudinal, ecological and
migration studies [4-6] and to interactions between envi-
ronmental and genetic factors when individuals become
exposed to an obesogenic environment [4,7].
In developing countries, the prevalence of diabetes is
markedly higher in urban than rural areas (e.g. 2.0% vs.
0.8% in Cameroon in 1999 or 14% vs. 5% in Egypt in
1995) [8,9]. There is also a gradient across socio-eco-
nomic development stages, e.g. a prevalence of DM in
African individuals of 2% in Cameroon, 9% in Jamaica,
11% in Trinidad and Tobago and 15% in Manchester
[8,10], which further emphasizes the role of environment
factors in populations of same genetic origin. However,
data on the prevalence, awareness and control of DM
remain limited in the African region.
Based on a population-based survey, we assessed the prev-
alence, awareness and control of diabetes (DM) in the
Republic of Seychelles, a rapidly developing country in
the African region. We also examined the relationship
between body mass index, fasting serum insulin and DM
and the proportion of all diabetic persons in the popula-
tion that could be attributed to excess body weight.
Methods
The Republic of Seychelles consists of over 100 islands
located in the Indian Ocean about 2000 km east of Kenya
and 2000 km north of Mauritius, in the African region.
Approximately 90% of the population of Seychelles lives
on the main island (Mahé) and most of the remaining
population resides on two nearby islands (Praslin and La
Digue). Although intermarriage has blurred racial differ-
ences in many Seychellois, it can be considered that
approximately two thirds of the population is of predom-
inantly African descent, 15% is of predominantly Cauca-
sian, Indian or Chinese descent, and a fifth is mixed
between these various groups. The population of Sey-
chelles can be considered as fairly urbanized in view of the
high density of the population and the facts that a large
proportion of the population commutes to the capital for
work and three quarters of workers are employed in serv-
ices [11,12]. The national gross domestic product per cap-
ita, in real terms, rose from US$ 2927 in 1980 to US$
5239 in 2004 [13], reflecting booming tourism and indus-
trial fishing industries. In Seychelles, cardiovascular dis-
ease and AIDS currently account for 38% and 1% of all
deaths, respectively [11]. Health care (inclusive medica-
tions) is provided free of charge to all inhabitants. The dis-
ease burden related to diabetes is significant in Seychelles
(e.g. a majority of lower limb amputations and a third of
all persons under hemodialysis are related to diabetes),
although the precise diabetes-related disease burden has
not been systematically determined yet.
A population-based examination survey for cardiovascu-
lar risk factors was conducted in 2004 under the auspices
of the Ministry of Health of the Republic of Seychelles.
The sampling frame consisted of a sex- and age- stratified
random sample of the population aged 25–64. Eligible
individuals were selected from a computerized database
derived from population censuses (last in 2002) thereafter
regularly updated by civil status authorities. Eligible par-
ticipants were invited to participate through a personal
letter requesting them to attend designated survey centers
on a particular date, fasting, between 7:30 and 11:00 am
and informing them that snacks would be provided on
the study center. Participants were free to participate and
gave informed written consent. The survey was approved
by the research and ethical board of the Ministry of Health
of the Republic of Seychelles.
A structured questionnaire was administered by trained
survey officers. The questions assessed, among other
items, if participants were "ever told by a doctor that they
had DM" and if they "were currently under treatment for
DM". If treatment was reported, participants were consid-
ered to have "known" DM. Family history of DM was
defined for participants who reported DM among a first
degree parents or siblings. Weight was measured with
electronic scales to 0.2 kg precision (Seca, Hamburg, Ger-
many) and height was measured with fixed stadiometers
to 0.5 cm precision (Seca). BMI was calculated as weight
divided by height squared (kg/m2). Blood pressure (BP)
refers to the average of the second and third of three meas-
urements (mercury sphygmomanometer, cuff size
adjusted to arm circumference).
Venous blood glucose was measured with a Cholestec
LDX, a point-of-care analyzer which is a reliable alterna-
tive to conventional laboratory devices [14]. The
Cholestec instrument separates blood cells from plasma
and measurements are therefore made on plasma. If glu-
cose was ≥ 5.6 mmol/l, another measurement was carried
out a few minutes later on capillary blood (Bayer, Ascentia
Elite [15]) and the mean of both readings was used. Of
note, the Ascentia Elite automatically adjusts reading toPage 2 of 9
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ment (Cholestec) and the second measurement (Ascentia
Elite) was as small as -0.15 mmol/l. Individuals who had
FBG ≥ 5.6 mmol/l and <7.0 mmol/l and were not aware
of having DM were submitted to an oral glucose tolerance
test (OGTT) using 75 g glucose dissolved in 300 ml water
and capillary glucose (Ascentia Elite) was measured 120
minutes later (2hBG). Glycated hemoglobin (HbA1c) was
measured in known or new cases of DM using a point-of-
care analyzer (DCA 2000, Bayer). The DCA 2000 has been
recommended for measurement of HbA1c outside of the
laboratory [16].
Categories of impaired glucose regulation were based on
the 2004 criteria of the American Diabetes Association
[17]. DM was defined as plasma FBG ≥ 7.0 mmol/l, 2hBG
≥ 11.1 mmol/l or current history of antidiabetic medica-
tion. IFG refers to FBG of 5.6–6.9 mmol/l. IGT was
defined as FBG <7.0 mmol/l and 2hBG of 7.8–11.0
mmol/l. Normal glucose tolerance (NGT) was defined as
2hBG <7.8 mmol/l. Normal fasting glucose (NFG) refers
to FBG values <5.6 mmol/l. Since subjects with NFG were
not tested for 2-hour glucose, we cannot determine DM
based on 2hBG ≥ 11.1 mmol/l and NFG.
Serum was obtained within 2 hours of blood collection
and immediately frozen to -20°C. Fasting serum insulin
(FSI) was measured at the University of Lausanne using
commercial RIA kits (LINCO Research Inc, Missouri,
USA). HOMA-IR (homeostasis model assessment of insu-
lin resistance) was calculated as [FSI (μU/ml) × FBG
(mmol/l)]/22.5 [18]. Blood lipids were measured using
standard methods (Hitachi 917 instrument and Roche
reagents) and low-density lipoprotein cholesterol (LDL-
C) calculated with the Friedewald formula.
Overall estimates in the population aged 25–64 were
standardized to the new age distribution of the World
Health Organization [19], using weighted "svy" com-
mands in Stata. Differences were tested with the chi-
square test and the t-test, respectively. For medians inter-
quartile ranges were calculated. Increases in mean FSI
across categories of impaired glucose regulation and BMI
categories were tested with the Cuzik trend test. The asso-
ciation between DM and body mass index categories was
analyzed with logistic regression adjusted for age and sex
and weighted for the age-stratified sampling frame ("svy-
logit"). We used a model aggregating men and women
since the interaction of BMI with sex was not significant.
We calculated the proportions of all DM cases in the pop-
ulation that could be attributable to overweight and obes-
ity (population attributable fraction, PAF) using the
weighted "aflogit" command in Stata. PAF is conceptually
computed as P(RR-1)/[1+P(RR-1)], where P is the preva-
lence of excess weight in the population [20] and RR is the
risk ratio of the exposure (excess weight) on the outcome
(DM). RR was estimated with the adjusted odds ratio
(OR) derived from the multivariate logistic regression
models and confidence intervals were based on asymp-
totic approximation [20]. Analyses were performed with
Stata 8.2 and p values less than 0.05 were considered sig-
nificant.
Results
1255 out of 1565 (80.3%) eligible individuals partici-
pated. Age-standardized mean values and prevalence rates
of selected characteristics are presented in Table 1. Mean
and median BMI and prevalence of overweight and obes-
ity were higher in women than in men (p < 0.001). Mean
FBG was similar in men and in women. Mean and median
FSI were higher in women than in men (p < 0.001).
Table 2 shows the prevalence of different categories of
impaired glucose regulation. The prevalence of DM was
particularly high in the oldest age group (55–64) in both
sexes. The prevalence of IFG was higher in men than in
women (p < 0.001). Since the measurement of FBG alone
may leave some DM persons undetected, an OGTT was
performed in individuals with FBG between 5.6–6.9
mmol/l. Using OGTT results for the diagnosis of DM (i.e.
2hBG ≥ 11.1 mmol/l) in addition to other criteria for DM,
the overall prevalence of DM increased by 2.1% (absolute
difference) or 22% (relative difference). The prevalence of
IGT did not differ significantly (p > 0.05) between gen-
ders. Of note, the prevalence of combined IFG/IGT is nec-
essarily equal to the prevalence of IFG in our study since
OGTT was performed in all subjects with IFG (i.e. FBG
between 5.6 and 6.9 mmol/l). Based on all three criteria
for DM, the prevalence of DM standardized for the actual
population of Seychelles in 2004 (i.e. not adjusted to the
WHO standard population) was 10.2% overall (95%CI:
8.6–11.9); men: 10.2% (7.7–12.7), women: 10.3 (8.0–
12.6). The slightly lower prevalence using actual age dis-
tribution in Seychelles vs. the WHO age distribution
reflects that the proportion of young vs. old people is
slightly larger in the actual population of Seychelles than
in the WHO standard age distribution.
Table 3 shows the odds ratios relating excess body weight
to DM and the proportions of DM cases in the population
that could be attributable to overweight and obesity, by
sex and overall. Estimates are standardized to the WHO
age distribution and regression models are also adjusted
for age. The prevalence of overweight and obesity was
higher in women than in men (p < 0.001). DM was
strongly associated with excess body weight (e.g. OR in
both men and women: 2.6 for BMI more vs. less than 25
kg/m2). The OR of DM associated with overweight and
obesity appearing in the table were virtually unchanged if
underweight (BMI <18.5 kg/m2, less than 6%) was alsoPage 3 of 9
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Table 1: Age-standardized means and medians of selected characteristics by sex
Men Women All
n 568 687 1255
Age (years)
25–34† % 22.2 21.7 21.9
35–44† % 23.6 25.6 24.7
45–54† % 27.8 26.3 27.0
55–64† % 26.4 26.4 26.4
Mean age† years 45.3 (0.5) 45.1 (0.4) 45.2 (0.3)
Mean age years 42.1 (0.5) 41.9 (0.4) 42.0 (0.3)
Mean body mass index kg/m2 25.5 (0.2) 28.3 (0.2) 26.9 (0.2)
Median body mass index kg/m2 25.2 (6.3) 27.8 (8.5) 26.4 (7.4)
Prevalence underweight % 4.6 (0.9) 3.3 (0.7) 4.0 (0.6)
Prevalence excess weight % 51.9 (2.1) 68.3 (1.9) 60.1 (1.4)
Prevalence obesity % 15.0 (1.5) 35.1 (1.8) 25.0 (1.2)
Mean fasting blood glucose mmol/l 6.0 (0.1) 5.7 (0.1) 5.9 (0.1)
Median fasting blood glucose mmol/l 5.5 (0.8) 5.3 (0.7) 5.4 (0.8)
Mean fasting serum insulin pmol/l 81.0 (3.1) 96.6 (2.8) 88.8 (2.1)
Median fasting serum insulin pmol/l 63.0 (48.6) 76.2 (55.2) 69.6 (52.2)
Mean HOMA-IR 4.1 (0.2) 4.5 (0.2) 4.3 (0.1)
Median HOMA-IR 2.7 (2.4) 3.1 (2.7) 2.9 (2.5)
Standard errors and inter-quartile ranges are indicated between brackets for means and medians, respectively. Except for age, all estimates are 
standardized for age [19].
Underweight: BMI <18.5 km/m2;excess weight: BMI ≥ 25 km/m2; obesity: BMI ≥ 30 kg/m2.
HOMA-IR: homeostasis model assessment of insulin resistance.
† Crude estimates. Other estimates are standardized for age.
Table 2: Prevalence of diabetes, impaired fasting glucose and impaired glucose tolerance (percent and 95% confidence interval) and 
proportion of diabetic persons aware of having diabetes
Men Women 25–64
25–34 35–44 45–54 55–64 25–34 35–44 45–54 55–64 Men Women All
n 126 134 158 150 149 176 181 181 568 687 1255
Diabetes (DM)
DM (2 criteria) 0.8 9.7 12.7 22.0 2.0 4.6 11.6 26.5 9.6 9.1 9.4
(0–2.3) (4.7–15) (7.5–18) (15–29) (0.2–2.3) (1.5–7.6) (6.9–16) (20–33) (7.4–12) (7.2–11) (7.9–11)
DM (3 criteria) 0.8 9.7 14.6 27.3 3.4 6.3 14.9 34.3 11.0 12.1 11.5
(0–2.3) (4.7–15) (9.1–20) (20–35) (0.5–2.9) (2.7–9.8) (9.7–20) (27–41) (8.7–13) (9.9–14) (9.9–13)
Impaired fasting glucose
IFG 16.0 35.1 42.4 32.9 5.4 13.6 26.5 37.0 30.4 18.0 24.2
(9.6–22) (27–43) (35–50) (25–40) (1.7–3.6) (8.6–19) (20–33) (30–44) (27–34) (15–21) (22–26)
Glucose tolerance
NGT (2hBG <7.8) 12.8 23.9 21.5 10.7 2.7 2.3 8.8 12.7 17.6 5.7 11.6
(6.9–19) (16–31) (15–28) (5.8–16) (0.1–2.6) (0.1–4.5) (4.7–13) (7.8–18) (14–21) (4.1–7.3) (9.8–14)
IGT (2hBG 7.8–11.0) 3.2 10.5 18.4 17.5 2.0 9.7 14.4 17.1 11.2 9.6 10.4
(0.1–6.3) (5.3–16) (12–24) (11–24) (0–2.3) (5.3–14) (9.2–20) (12–23) (8.7–14) (7.5–12) (8.8–12)
DM (2hBG ≥ 11.1) 0.0 0.8 2.5 4.7 0.7 1.7 3.3 7.2 1.6 2.7 2.1
(0–2.2) (0.1–5.0) (1.3–8.1) (0–1.3) (0–3.6) (0.7–5.9) (3.4–11) (0.7–2.5) (1.6–3.8) (1.4–2.9)
Aware of DM (among DM)
0.0 30.8 45.0 60.6 0.0 50.0 61.9 64.6 47.1 61.5 53.9
(4.7–56) (23–67) (44–77) (13–87) (41–83) (51–78) (35–59) (50–73) (46–62)
FBG: fasting blood glucose; IFG: impaired fasting glucose; 2hBG: blood glucose 2 hours after oral tolerance test; NGT: normal glucose tolerance; 
IGT: impaired glucose tolerance; DM: diabetes mellitus.
DM (2 criteria): FBG ≥ 7.0 mmol/l or history of treatment for DM.
DM (3 criteria): FBG ≥ 7.0 mmol/l, history of treatment for DM, or 2hBG ≥ 11.1 mmol/l.
Oral glucose tolerance test was administered to all individuals with FBG of 5.6–6.9 mmol/l without previous history of diabetes.
Overall prevalence estimates are standardized for age [19].
BMC Public Health 2007, 7:163 http://www.biomedcentral.com/1471-2458/7/163factored in the analysis (the reference BMI category being
then 18.5–24.9 kg/m2). The proportion of all DM cases in
the entire population that could be attributed to excess
weight was 49% (95%: 35%–61%). By using lower cut off
values to define the reference BMI category -as used in
other studies [21]-, the proportions of all cases of DM in
the population that are attributable to excess weight
increased to 58% (95% CI: 56%–60%) for a BMI cut off
set at ≥ 24 kg/m2 and to 73% (71%–74%) for a BMI cut
off set at ≥23 kg/m2.
In a separate model, the odds for having DM were 2.4
(1.7–3.5) times higher in persons with family history of
DM compared to those without it. This OR for family his-
tory of DM was virtually identical whether BMI was
included in multivariate analysis or not and whether
models were run in all participants, men or women.
Adjusting for age, sex and BMI, the proportion of all DM
cases in the population that could be attributable to fam-
ily history of DM was 25% (14–35%).
Figure 1 shows that mean FSI increased gradually across
both categories of BMI and categories of impairment of
glucose metabolism (i.e. NFG, IFG, IGT, DM). In separate
analyses adjusted for age and sex (analyses not shown),
the same relationships were found between FSI and both
categories of impaired glucose regulation and BMI catego-
ries (p for trend < 0.001 for both). In these analyses, DM
patients who were on insulin treatment (n = 10) were
excluded. Analyses with HOMA-IR instead of FSI showed
same patterns of association with categories of BMI and
glucose metabolism impairment.
Figure 2 shows, among all persons reporting current anti-
diabetic treatment (n = 80), the proportions who achieved
different levels of blood glucose (based on HbA1c), BP
and LDL-cholesterol. Less than a quarter of diabetic per-
sons under treatment achieved recommended treatment
targets for any of these three considered cardiometabolic
conditions, i.e. HbA1c <7, BP <130/80 mmHg, and LDL-
cholesterol <2.6 mmol/l. Less than 50% of treated
patients achieved levels HbA1c <8, BP <140/90 mmHg
and LDL-cholesterol <3.5 mmol/l. Almost 40% had
HbA1c ≥ 10 and approximately 20% had BP ≥ 160/100 or
LDL cholesterol ≥ 5 mmol/l. The prevalence of high blood
pressure and hypercholesterolemia in this population
were published earlier [22].
Discussion
We found a high prevalence of DM in a rapidly develop-
ing country in the African region, a substantial proportion
of persons unaware of DM in the population, limited car-
diometabolic control among treated diabetic persons, and
a strong association of DM with excess weight. These find-
ings in Seychelles add to the few population-based data
on DM available in the African region and may be repre-
sentative of other countries experiencing rapid socio-eco-
nomic development and concurrent lifestyle changes.
The prevalence of DM is higher in Seychelles than in pre-
dominantly rural African regions such as Nigeria [3],
Cameroon [23] or Tanzania [24] but as high as in urban
settings in South Africa [25] and Egypt [9]. The prevalence
of DM in Seychelles is however lower than in the island of
Mauritius [4] despite larger BMI in the population of Sey-
chelles than in Mauritius. The difference between these
two neighbor islands of similar economic development
may partly relate to their different ethnic composition
(predominantly African in Seychelles and predominantly
Indian in Mauritius) since Indian descent is a known risk
factor for DM [4,26]. Compared to non African countries,
the prevalence of DM in the Seychelles is similar to esti-
mates in urban Saudi Arabia [27], several regions of
Europe [28], the United States [29] and urban India [6]
but higher than in Mongolia [30], Bangladesh [31], the
Table 3: Relationship between categories of body mass index (BMI) and diabetes and proportion of diabetic persons in the entire 
population that is attributable to overweight and obesity (95% confidence intervals in brackets)
Men Women All
Prevalence (%) Odds ratio* PAF (%) Prevalence (%) Odds ratio* PAF (%) Prevalence (%) Odds ratio* PAF (%)
Overweight
(BMI: 25–29 kg/m2) 37 (33–41) 2.1 (1.9–2.2) 26 (16–36) 33 (30–37) 2.6 (2.3–3.0) 20 (12–26) 35 (32–38) 3.5 (3.2–3.8) 23 (14–31)
Obesity
(BMI ≥ 30 kg/m2) 15 (12–18) 2.6 (2.4–2.9) 17 (11–23) 35 (32–29) 4.5 (4.0–5.1) 36 (25–45) 25 (23–28) 3.3 (2.0–5.5) 26 (15–36)
Overweight or obesity
(BMI ≥ 25 kg/m2) 52 (48–56) 2.2 (2.1–2.4) 43 (29–55) 68 (64–72) 3.6 (3.2–4.1) 56 (41–67) 60 (57–63) 2.6 (2.4–2.8) 49 (35–61)
All models are adjusted for age.
Estimates are standardized for age [19].
BMI: body mass index.
PAF: population attributable fraction.
* reference category: BMI <25 kg/m2.Page 5 of 9
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and rural Saudi Arabia [27].
A few factors in our study may tend to over or underesti-
mate the true prevalence of DM in the population. Possi-
ble biases for underestimation are several. First we did not
include individuals older than 64 years, an age group in
which the prevalence of DM is likely to be particularly
high [4,29,36,37]. Second, we did not perform an OGTT
in individuals with FBG <5.6 mmol/l and we could have
missed a few DM cases in persons with normal fasting glu-
cose but pathologically high post meal levels. The number
of such cases is however expected to be small [38]. Third,
underestimation might also have occurred if non partici-
pation was related to diabetes-related diseases (e.g. leg
wounds, renal failure, stroke, etc). On the other hand,
overestimation may have occurred if some persons with
elevated FBG were not fasting. This bias was minimized as
persons who reported not to be fasting were invited to
attend the survey on another day. Also, elevated fasting
blood glucose was not repeated on a separate day. Overall,
it is possible that factors that over or underestimate the
prevalence of DM might balance each other and our prev-
alence estimates may be close to the true prevalence of
DM in the adult population.
The high prevalence of IFG and/or IGT suggests that the
DM epidemic has not yet plateaued in Seychelles. Indeed,
IGT [39] and IFG [40] are strong predictors of DM [41]
and these pre-diabetes conditions may occur in up to 60%
of individuals several years before DM develops [42]. It
has been reported that in the USA, where the prevalence
of IFG and IGT is respectively 26% and 15%, approxi-
mately 25% of individuals with IFG/IGT will progress to
diabetes, 50% will remain in their abnormal glycemic
state, and 25% will revert to normal glucose tolerance
(NGT) over a period of 3 to 5 years [43]. Hence, the sub-
stantially high proportion of pre-diabetes in Seychelles
predicts a further increase in the prevalence of DM over
the next few years, consistent with projections in other
African countries in epidemiological transition
[23,26,36].
While the proportion of all diabetes cases in the popula-
tion who are aware of having DM ("aware") is approxi-
mately 50%, similar low proportions (about 50%) are
also typically found in middle- or high-income countries
such as Egypt [9], Saudi Arabia [27], Spain [33] and the
U.S. [44]. Such low figures emphasize the difficulty to
identify a disease (DM) that is most often silent for many
years after onset.
Level of control of blood glucose (HbA1c: glycatedhemo-globin), bl od pressure (BP) and low-density lipoprotein cho-lest r l (LDL-C) in all participants receivin  hypoglyc mi  treatment (n = 80)Figu e 2
Level of control of blood glucose (HbA1c: glycated-
hemoglobin), blood pressure (BP) and low-density 
lipoprotein cholesterol (LDL-C) in all participants 
receiving hypoglycemic treatment (n = 80). Cut off val-
ues for control categories are <7.0, 7.0–7.9, 8–9.9, ≥ 10 for 
HbA1c; <130/80; 130-9/80-9; 140-59/90–99, ≥ 160/100 
mmHg for BP; and <2.6, 2.6–3.4, 3.5–4.9, ≥ 5 mmol/l for 
LDL-cholesterol. Blue: within recommended treatment tar-
gets.
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BMC Public Health 2007, 7:163 http://www.biomedcentral.com/1471-2458/7/163We found that a large proportion of diabetic persons
under anti-diabetic treatment had levels of blood sugar
(as assessed by HbA1c), blood pressure, and LDL-choles-
terol above the recommended therapeutic targets. Limited
clinical control of DM is also found in high income west-
ern countries such as the USA [45]. In the USA, only 37%
of DM patients had HbA1c levels <7.0%, only 35.8%
achieved target blood pressure (<130/80 mmHg) and
51.8% of DM patients had hypercholesterolemia [45].
This further illustrates the great difficulty in achieving and
sustaining good control of blood glucose, blood pressure
and blood lipids in chronic diseases such as DM. In addi-
tion, limited cardiometabolic control is known to be even
more difficult to achieve in DM patients who are over-
weight -a frequent occurrence- because of underlying
insulin resistance [45,46].
DM was associated strongly with overweight, independ-
ent of age, sex and family history of DM. This relationship
has been found consistently in other populations
[27,32,33,35,47] and, for example, 90% of new DM cases
among both African and white Americans had BMI ≥ 23
kg/m2 [21]. In our study, half of all DM cases could be
attributed to overweight or obesity. This proportion rose
to 73% if normal weight was considered for BMI <23 kg/
m2 instead of BMI <25 kg/m2. In a Taiwanese cohort as
much as 71% of DM cases were attributable to a BMI ≥ 25
kg/m2[48].
It is important to attempt to determine if the prevalence
rates of DM and overweight (i.e. "diabesity") has
increased over time in order to anticipate epidemiological
trends and inform health care policy. The prevalence of
DM was assessed for the first time in 1989 in the popula-
tion of Seychelles [49] and it was found that 3.4% of men
and 4.6% of women had DM. Using the same criteria in
1989 and 2004 (i.e. known diabetes and/or elevated fast-
ing blood glucose) and the same age standardization
(new WHO age distribution [20]) the prevalence of DM
significantly increased between the two years in men
(from 6.2% to 9.6%) and in women (from 6.1% to 9.1%).
Since the survey methods were not identical in 1989 and
2004 (e.g. glucometers), there is a degree of uncertainty in
these trend estimates. However, a true increase in the prev-
alence of DM over time is consistent with the large
increase in obesity in men (from 4.3% to 15.0%) and
women (from 27.9% to 35.1%). Increasing prevalence of
overweight/obesity in the population in the interval is
likely related to increasingly sedentary behaviors and
larger caloric intake. Currently, more than 75% of workers
are employed in services (vs. only 20% in industry and 5%
in agriculture) [11,12]. The number of both private cars
and passengers transported by public buses has doubled
in the past 10 years (figures from the Licensing Authority
and the Seychelles Public Transport Company, respec-
tively). On the other hand, food balance sheets indicate
that calorie availability per capita has increased substan-
tially in Seychelles, e.g. from 1800 kcal in 1965, 2300 kcal
in the late 1980s, and above 2400 kcal in the early 2000s
[50]. The proportion of carbohydrates has decreased over
time (74% of total calories in 1965 and 55% in 2000)
while the proportion of fats has increased (16% in 1965
and 32% in 2000) [50]. The production of carbonated
soft drinks by the main local manufacturer has tripled in
the past 25 years (figures from Seychelles Breweries Ltd).
Conclusion
The prevalence of DM in Seychelles has reached or
exceeded levels typically found in several middle- or high-
income countries. The strong association between DM
and excess body weight emphasizes the importance of
weight control interventions at a population level as a cor-
nerstone strategy to curb the "diabesity" epidemic [51].
From a clinical perspective, the substantial proportion of
persons unaware of having DM calls for improved early
detection of diabetic persons. The high proportion of
treated diabetic persons with insufficient cardiometabolic
control stresses the need for intensifying clinical care to
diabetic patients in order to minimize complications [52].
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